Literature DB >> 30318137

Lichen planus and lichenoid dermatoses: Conventional and emerging therapeutic strategies.

Christos Tziotzios1, Timothy Brier2, John Y W Lee2, Ryo Saito2, Chao-Kai Hsu2, Kapil Bhargava2, Catherine M Stefanato3, David A Fenton2, John A McGrath2.   

Abstract

Having reviewed the diverse clinical subtypes of lichenoid disease and the postulated molecular basis thereof in the first article in this 2-part continuing medical education series, we discuss herein the existing and emerging treatment strategies in the most common clinical forms of lichenoid inflammation and provide an overview of their pharmacodynamics and evidence base. The scope of this review is not to exhaustively discuss treatment modalities for all lichenoid variants discussed in the previous article of this series. Instead, the focus will be on frequently encountered subtypes of lichen planus and on linking mechanisms of disease with mechanisms of drug action. Future directions and potential avenues for translational research will also be discussed.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  emerging drugs for lichenoid inflammation; lichen planus therapeutics; lichenoid variant therapeutics

Mesh:

Substances:

Year:  2018        PMID: 30318137     DOI: 10.1016/j.jaad.2018.02.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Lichen Planopilaris and Low-Level Light Therapy: Four Case Reports and Review of the Literature About Low-Level Light Therapy and Lichenoid Dermatosis.

Authors:  Michael J Randolph; Waleed Al Salhi; Antonella Tosti
Journal:  Dermatol Ther (Heidelb)       Date:  2020-02-14

2.  Effectiveness of narrowband UVB phototherapy and psoralen plus UVA photochemotherapy in the treatment of generalized lichen planus: Results from a large retrospective analysis and an update of the literature.

Authors:  Benedikt Weber; Elias Marquart; Sonja Radakovic; Adrian Tanew
Journal:  Photodermatol Photoimmunol Photomed       Date:  2021-08-11       Impact factor: 3.254

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.